Multivariate analysis for risk of transformation or risk of death in patients with CP-CML
| BCR-ABL <10% at 3 mo . | Not included in MVA . | Included in MVA . | ||
|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | |
| TFS | ||||
| Age | 1.03 (1.00-1.05) | .03 | 1.03 (1.01-1.06) | .01 |
| Blasts in BM (%) | 1.15 (1.00-1.33) | .05 | 1.18 (1.03-1.37) | .01 |
| Basophils in BM (%) | 1.07 (0.95-1.20) | .28 | 1.05 (0.90-1.16) | .74 |
| CCA/Ph− (−Y)* | 0.80 (0.18-3.44) | .76 | 0.93 (0.21-4.04) | .94 |
| CCA/Ph− (non −Y)* | 2.81 (1.15-6.89) | .02 | 2.17 (0.86-5.50) | .10 |
| BCR-ABL <10% at 3 mo† | — | — | 3.96 (1.80-8.73) | <.01 |
| OS | ||||
| Age | 1.06 (1.03-1.08) | <.01 | 1.06 (1.03-1.08) | <.01 |
| Sokal score‡ | ||||
| Intermediate | 1.01 (0.55-1.86) | .96 | 1.03 (0.56-1.89) | .92 |
| High | 1.74 (0.78-3.90) | .17 | 1.65 (0.73-3.70) | .22 |
| CCA/Ph− (−Y)* | 0.91 (0.35-2.34) | .84 | 1.03 (0.40-2.68) | .94 |
| CCA/Ph− (non −Y)* | 1.62 (0.55 −3.63) | .24 | 1.39 (0.61-3.15) | .43 |
| BCR-ABL <10% at 3 mo† | — | — | 2.39 (1.24-4.60) | <.01 |
| BCR-ABL <10% at 3 mo . | Not included in MVA . | Included in MVA . | ||
|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | |
| TFS | ||||
| Age | 1.03 (1.00-1.05) | .03 | 1.03 (1.01-1.06) | .01 |
| Blasts in BM (%) | 1.15 (1.00-1.33) | .05 | 1.18 (1.03-1.37) | .01 |
| Basophils in BM (%) | 1.07 (0.95-1.20) | .28 | 1.05 (0.90-1.16) | .74 |
| CCA/Ph− (−Y)* | 0.80 (0.18-3.44) | .76 | 0.93 (0.21-4.04) | .94 |
| CCA/Ph− (non −Y)* | 2.81 (1.15-6.89) | .02 | 2.17 (0.86-5.50) | .10 |
| BCR-ABL <10% at 3 mo† | — | — | 3.96 (1.80-8.73) | <.01 |
| OS | ||||
| Age | 1.06 (1.03-1.08) | <.01 | 1.06 (1.03-1.08) | <.01 |
| Sokal score‡ | ||||
| Intermediate | 1.01 (0.55-1.86) | .96 | 1.03 (0.56-1.89) | .92 |
| High | 1.74 (0.78-3.90) | .17 | 1.65 (0.73-3.70) | .22 |
| CCA/Ph− (−Y)* | 0.91 (0.35-2.34) | .84 | 1.03 (0.40-2.68) | .94 |
| CCA/Ph− (non −Y)* | 1.62 (0.55 −3.63) | .24 | 1.39 (0.61-3.15) | .43 |
| BCR-ABL <10% at 3 mo† | — | — | 2.39 (1.24-4.60) | <.01 |
This multivariate model included covariates with P < .05 in the univariate analysis. Another model using the backward elimination method was also used and led to similar results as detailed in supplemental Tables 1-12 and Figures 1-4.
MVA, multivariate analysis.
CCA/Ph− groups were compared with the control group without additional chromosomal abnormalities.
There were 46 patients in which the BCR-ABL level at 3 mo was not available and was included as a separate group in the univariate analysis as detailed in the supplemental Tables 1-12. Not achieving a BCR-ABL <10% at 3 mo was compared with the group in which this level was achieved.
Low Sokal score group was used as a reference for the other Sokal score groups.